Terns Pharma Secures Global Rights for Key Drug Candidate, But Valuation Questions Loom
Terns Pharmaceuticals has renegotiated its licensing deal for TERN-701, gaining exclusive worldwide rights outside key Asian markets. The strategic move comes after a period of explosive stock performance, but analysts are now scrutinizing whether its premium valuation is justified given its clinical-stage pipeline and lack of revenue.